SEARCH

SEARCH BY CITATION

References

  • Aslanian, A.M., Fletcher, B.S. & Kilberg, M.S. (2001) Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. The Biochemical Journal, 357, 321328.
  • Chan, J.K.C., Sin, V.C., Wong, K.F., Ng, C.S., Tsang, W.Y.W., Chan, C.H., Cheung, M.M.C. & Lau, W.H. (1997) Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood, 89, 45014513.
  • Chaperot, L., Bendriss, N., Manches, O., Gressin, R., Maynadie, M., Trimoreau, F., Orfeuvre, H., Corront, B., Feuillard, J., Sotto, J.J., Bensa, J.C., Briere, F., Plumas, J. & Jacob, M.C. (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood, 97, 32103217.
  • Clarkson, B., Krakoff, I., Burchenal, J., Karnofsky, D., Golbey, R., Dowling, M., Oettgen, H. & Lipton, A. (1970) Clinical results of treatment with E.coli l-asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer, 25, 279305.
  • Egashira, M., Kawamata, N., Sugimoto, K., Kaneko, T. & Oshimi, K. (1999) P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporine A and its analogue, PSC833. Blood, 93, 599606.
  • Ertel, I.J., Nesbit, M.E., Hammond, D., Weiner, J. & Sather, H. (1979) Effective dose of l-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from a children's cancer study group. Cancer Research, 39, 38933896.
  • Feuillard, J., Jacob, M.C., Valensi, F., Maynadie, M., Gressin, R., Chaperot, L., Arnoulet, C., Brignole-Baudouin, F., Drenou, B., Duchayne, E., Falkenrodt, A., Garand, R., Homolle, E., Husson, B., Kuhlein, E., Calvez, G.L., Sainty, D., Sotto, M.F., Trimoreau, F. & Bene, M.C. (2002) Clinical and biologic features of CD4+CD56+ malignancies. Blood, 99, 15561563.
  • Fumarola, C., Zerbini, A. & Guidotti, G.G. (2001) Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis. Cell Death and Differentiation, 8, 10041013.
  • Gong, J.H., Maki, G. & Klingemann, H.G. (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia, 8, 652658.
  • Hercend, T. & Schmidt, R.E. (1988) Characteristics and uses of natural killer cells. Immunology Today, 9, 291293.
  • Hutson, R.G., Kitoh, T., Moraga, D.A., Cosic, S., Schuster, S.M. & Kilberg, M.S. (1997) Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. American Journal of Physiology. Cell Physiology, 272, 16911699.
  • Imamura, N., Kusunoki, Y., Kawa-Ha, K., Yomura, K., Hara, J., Oda, K., Abe, K., Dohy, H., Inada, T., Kajihara, H. & Kuramoto, A. (1990) Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature: possible existence of a new clinical entity originating from the third lineage of lymphoid cells. British Journal of Haematology, 75, 4959.
  • Irino, T., Kitoh, T., Koami, K., Kashima, T., Mukai, K., Takeuchi, E., Hongo, T., Nakahata, T., Schuster, S.M. & Osaka, M. (2004) Establishment of real-time PCR method for quantitative analysis of asparagine synthetase expression. The Journal of Molecular Diagnostics, 6, 217224.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon.
  • Kwong, Y.L., Chan, A.C.L., Liang, R., Chiang, A.K.S., Chim, C.S., Chan, T.K., Todd, D. & Ho, F.C.S. (1997) CD56+ NK lymphomas: clinicopathologic features and prognosis. British Journal of Haematology, 97, 821829.
  • Matsumoto, Y., Nomura, K., Kanda, Y., Fujita, Y., Nakao, M., Ueda, K., Horiike, S., Yokota, S., Kusuzaki, K., Kitoh, T., Watanabe, A. & Taniwaki, M. (2003) Successful treatment with Erwinial-sparaginase for recurrent natural killer/T cell lymphoma. Leukemia & Lymphoma, 44, 879882.
  • Oshimi, K. (2003) Leukemia and lymphoma of natural killer lineage cells. International Journal of Hematology, 78, 1823.
  • Pastan, I. & Gottesman, M.M. (1994) Multidrug resistance. Annual Review of Medicine, 42, 277286.
  • Remarkers-van Woerden, N.L., Pieters, R., Loonen, A.H., Hubeek, I., Drunen, E., Beverloo, H.B., Slater, R.M., Harbott, J., Seyfarth, J., van Wering, E.R., Hahlen, K., Schmiegelow, K., Janka-Schaub, G.E. & Veerman, A.J.P. (2000) TEL/AML1 gene fusion is related to in vitro drug sensitivity for l-asparaginase in childhood acute lymphoblastic leukemia. Blood, 96, 10941099.
  • Robertson, M.J. & Ritz, J. (1990) Biology and clinical relevance of human natural killer cells. Blood, 76, 24212438.
  • Sheng, S., Moraga, D.A., Van Heeke, G. & Schuster, S.M. (1992) High-level expression of human asparagine synthetase and production of monoclonal antibodies for enzyme purification. Protein Expression and Purification, 3, 337346.
  • Siu, L.L.P., Chan, J.K.C. & Kwong, Y.L. (2002) Natural killer cell malignancies: clinicopathologic and molecular features. Histology and Histopathology, 17, 539554.
  • Stams, W.A.G., den Boer, M.L., Beverloo, B., Meijerrink, J.P.P., Stigter, R.L., van Wering, E.R., Janka-Schaub, G.E., Slater, R. & Pieters, R. (2003) Sensitivity to l-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood, 101, 27432747.
  • Stams, W.A.G., den Boer, M.L., Holleman, A., Appel, I.M., Beverloo, B., van Wering, E.R., Janka-Schaub, G.E., Evans, W.E. & Pieters, R. (2005) Asparagine synthetase expression is linked with l-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood, 105, 42234225.
  • Story, M.D., Voehringer, D.W., Stephens, L.C. & Meyn, R.E. (1993) l-Asparaginase kills lymphoma cells by apoptosis. Cancer Chemotherapy and Pharmacology, 32, 129133.
  • Sugimoto, K., Yamada, K., Egashira, M., Yazaki, Y., Hirai, H., Kikuchi, A. & Oshimi, K. (1998) Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells. Blood, 91, 14071417.
  • Sugimoto, K., Tamayose, K., Sasaki, M., Hayashi, K. & Oshimi, K. (2002) Low-dose doxorubicin-induced necrosis in Jurkat cells and its acceleration and conversion to apoptosis by antioxidants. British Journal of Haematology, 118, 229238.
  • Tefferi, A., Li, C.Y., Witzig, T.E., Dhodapkar, M.V., Okuno, S.H. & Phyliky, R.L. (1994) Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood, 84, 27212725.
  • Trinchieri, G. (1989) Biology of natural killer cells. Advances in Immunology, 47, 187376.
  • Tsuchiyama, J., Yoshino, T., Mori, M., Kondoh, E., Oka, T., Akagi, T., Hiraki, A., Nakayama, H., Shibuya, A., Ma, Y., Kawabata, T., Okada, S. & Harada, M. (1998) Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood, 92, 13741383.
  • Ueno, T., Ohtawa, K., Mitsui, K., Kodera, Y., Hiroto, M., Matsushima, A., Inada, Y. & Nishimura, H. (1997) Cell cycle arrest and apoptosis of leukemia cells induced by l-asparaginase. Leukemia, 11, 18581861.
  • Wagner, A., Hempel, G., Gumbinger, H.G., Jurgens, H. & Boos, J. (1999) Pharmacokinetics of anticancer drugs in vitro. Advance in Experimental Medicine and Biology, 457, 397407.
  • Yamaguchi, M., Kita, K., Miwa, H., Nishii, K., Oka, K., Ohno, T., Shirakawa, S. & Fukumoto, M. (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer, 76, 23512356.
  • Yamamoto, T., Iwasaki, T., Watanabe, N., Oshimi, K., Naito, M., Tsuruo, T. & Kobayashi, Y. (1993) Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood, 81, 13421346.
  • Yong, W., Zheng, W., Zhang, Y., Zhu, J., Wei, Y., Zhu, D. & Li, J. (2003) l-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. International Journal of Hematology, 78, 163167.